Antiviral Pharmacology

Correct Answer

C — Lamivudine

Rationale

Lamivudine is classified as a cytidine analogue nucleoside reverse transcriptase inhibitor. It is structurally related to the cytidine nucleoside and inhibits hepatitis B virus reverse transcriptase after intracellular phosphorylation to its active triphosphate form. Tenofovir disoproxil fumarate and adefovir dipivoxil are acyclic phosphonate nucleotide analogues — they differ from nucleoside analogues in carrying a preformed phosphonate group. Entecavir is a guanosine nucleoside analogue. The cytidine vs. guanosine vs. phosphonate nucleotide distinction is classification vocabulary for hepatitis B virus nucleos(t)ide analogues.

Correct Answer

A — Nirmatrelvir

Rationale

Nirmatrelvir is classified as a peptidomimetic inhibitor of the SARS-CoV-2 main protease, administered with ritonavir as a pharmacokinetic booster that inhibits cytochrome P450 3A4 to maintain therapeutic nirmatrelvir plasma concentrations. Remdesivir is a nucleotide analogue prodrug that inhibits ribonucleic acid-dependent ribonucleic acid polymerase and is given intravenously. Baloxavir marboxil is a cap-dependent endonuclease inhibitor used for influenza. Molnupiravir is a ribonucleoside analogue prodrug that introduces lethal mutations into viral ribonucleic acid through an error catastrophe mechanism, targeting the SARS-CoV-2 ribonucleic acid polymerase.

Correct Answer

D — Molnupiravir

Rationale

Molnupiravir is classified as an oral ribonucleoside analogue prodrug approved for treatment of mild-to-moderate COVID-19 in high-risk adults who are not hospitalized. Remdesivir is a nucleotide analogue prodrug that targets ribonucleic acid-dependent ribonucleic acid polymerase but is administered intravenously, not orally, and is approved for hospitalized patients. Sofosbuvir is an NS5B nucleotide analogue chain terminator used for hepatitis C virus, not COVID-19. Baloxavir marboxil is a cap-dependent endonuclease inhibitor used for influenza, not a ribonucleoside analogue and not approved for COVID-19.

Correct Answer

B — Sotrovimab

Rationale

Sotrovimab is classified as a broadly neutralizing monoclonal antibody targeting a conserved epitope on the SARS-CoV-2 spike protein. It was developed to target an epitope conserved across sarbecoviruses with the goal of providing broad coverage against emerging variants. Nirsevimab targets the respiratory syncytial virus fusion protein, not SARS-CoV-2. Palivizumab also targets the respiratory syncytial virus fusion protein. Rituximab targets the human CD20 antigen expressed on B lymphocytes and has no antiviral activity against SARS-CoV-2.

Correct Answer

C — Tenofovir disoproxil fumarate and tenofovir alafenamide

Rationale

Tenofovir disoproxil fumarate and tenofovir alafenamide are both classified as acyclic phosphonate nucleotide analogues — they carry a preformed phosphonate group in place of the normal phosphate ester bond, distinguishing them from nucleoside analogues that lack this preformed phosphonate. Lamivudine and emtricitabine are cytidine nucleoside analogues. Entecavir is a guanosine nucleoside analogue and telbivudine is a thymidine nucleoside analogue — neither is a phosphonate nucleotide analogue. Adefovir dipivoxil is an acyclic phosphonate nucleotide analogue, but entecavir is not, making that pair incorrect.

Correct Answer

A — Zidovudine

Rationale

Zidovudine is classified as a thymidine analogue nucleoside reverse transcriptase inhibitor — it is structurally modeled on the thymidine nucleoside. Emtricitabine and lamivudine are cytidine analogues. Abacavir is a guanosine analogue. The thymidine, cytidine, and guanosine analogue classifications are core vocabulary for the nucleoside reverse transcriptase inhibitor class.

Correct Answer

D — HIV reverse transcriptase lacks proofreading activity, generating approximately 10 billion virions daily in untreated infection; every possible single-point mutation already exists in the viral population before any drug is administered, and drug selection merely amplifies pre-existing resistant variants

Rationale

The high mutation rate of HIV reverse transcriptase — which lacks the proofreading exonuclease activity present in cellular deoxyribonucleic acid polymerases — combined with the extraordinary replication rate of HIV (approximately 10 billion virions per day in untreated infection) ensures that every possible single-nucleotide substitution is generated many times daily within a single infected person. Drug-resistant variants therefore pre-exist in the quasispecies before treatment begins. When monotherapy is initiated, drug pressure kills drug-sensitive wild-type virus while sparing the pre-existing resistant minority variant, which then replicates to dominate the population. Drugs do not induce resistance mutations; they select variants that already exist.

Correct Answer

B — S31N imposes negligible fitness cost on influenza virus, allowing resistant strains to replicate and transmit as efficiently as wild-type in drug-naive hosts; thymidine analogue mutations impose a meaningful fitness cost on HIV, reducing competitive fitness against wild-type virus when drug pressure is removed

Rationale

Fitness cost — the degree to which a resistance mutation impairs viral replication in the absence of drug — is the primary determinant of whether resistant strains spread in the human population without drug selection pressure. S31N in influenza M2 has negligible fitness cost: resistant influenza A strains replicate and transmit as efficiently as wild-type, allowing rapid community spread independent of drug use. Thymidine analogue mutations in HIV carry a meaningful fitness cost, reducing replicative capacity relative to wild-type virus; in drug-naive individuals, wild-type virus outcompetes thymidine analogue mutation-carrying virus and the mutations do not accumulate to dominance. This principle — that fitness cost, not drug selection pressure alone, determines resistance ecology — is the central concept of resistance epidemiology.

Correct Answer

A — K103N confers high-level non-nucleoside reverse transcriptase inhibitor resistance with low fitness cost, allowing K103N-carrying virus to persist in the quasispecies and transmit efficiently in the absence of drug pressure

Rationale

K103N confers high-level resistance to efavirenz and nevirapine through a single mutation in the reverse transcriptase gene while imposing low fitness cost on the virus. Because K103N-carrying HIV replicates efficiently without drug pressure, this variant persists in the viral quasispecies of untreated source partners and can be transmitted to newly infected individuals who have never received antiretroviral therapy. In contrast, resistance mutations associated with integrase strand transfer inhibitors and protease inhibitors carry higher fitness costs, causing resistant variants to be outcompeted by wild-type virus in the absence of drug selection, reducing the probability of transmission and persistence in drug-naive hosts. The practical implication is that baseline genotypic resistance testing is recommended before initiating antiretroviral therapy to detect transmitted non-nucleoside reverse transcriptase inhibitor resistance that might compromise first-line regimen efficacy.

Correct Answer

C — Because NS5A inhibitors work at very low concentrations, even a small reduction in binding affinity from a single resistance mutation can shift the effective inhibitory concentration above what is achievable in plasma, conferring clinically meaningful resistance

Rationale

The genetic resistance barrier of an antiviral reflects how many mutations are required to reduce drug susceptibility to a clinically relevant degree, not simply how potent the drug is. NS5A inhibitors achieve their antiviral effect at picomolar concentrations — their exceptional potency paradoxically makes them more vulnerable to resistance because the drug-target interaction has a very narrow margin. A single resistance-associated substitution at NS5A positions 28, 30, 31, or 93 can reduce drug binding affinity sufficiently to raise the effective inhibitory concentration above achievable plasma concentrations. NS5B polymerase inhibitors and NS3 protease inhibitors require multiple mutations or a more impactful single mutation to confer clinically meaningful resistance. This is why first-generation NS5A inhibitors were affected by pre-existing resistance-associated substitutions in approximately 10 to 15 percent of genotype 1a-infected patients, whereas second-generation pangenotypic combinations maintain high response rates despite these substitutions.

Correct Answer

D — Acyclovir and all thymidine kinase-dependent analogues require viral thymidine kinase for initial phosphorylation to their active forms; foscarnet requires no phosphorylation and cidofovir is activated by cellular enzymes, so thymidine kinase-null mutations have no effect on either agent

Rationale

The cross-resistance pattern of herpesvirus drug resistance is mechanistically determined by the drug activation pathway. Acyclovir, valacyclovir, penciclovir, and famciclovir all require viral thymidine kinase for initial phosphorylation; thymidine kinase-null or thymidine kinase-partial mutations therefore confer simultaneous resistance to all of them. Foscarnet directly inhibits the viral deoxyribonucleic acid polymerase at the pyrophosphate binding site without requiring any phosphorylation — thymidine kinase mutations have no effect on its activity. Cidofovir is an acyclic nucleoside phosphonate activated entirely by cellular kinases without requiring viral thymidine kinase or any other viral enzyme — thymidine kinase mutations likewise have no effect. When resistance is instead caused by deoxyribonucleic acid polymerase mutations, the cross-resistance pattern depends on the structural overlap of the binding sites of the various agents at the polymerase active site, which differs from the thymidine kinase-based pattern.

Correct Answer

B — Sanger sequencing detects mutations present in more than approximately 20 percent of the viral population; next-generation sequencing detects minority variants at 1 to 5 percent frequency, but the clinical significance of low-frequency minority variants remains incompletely established

Rationale

Sanger sequencing, the historical standard for HIV genotypic resistance testing, reads the consensus sequence of the viral population and reliably detects mutations present in more than approximately 20 percent of sequenced reads. Next-generation sequencing — also called deep sequencing or ultradeep sequencing — uses massively parallel sequencing to detect minority variants present at frequencies as low as 1 to 5 percent, revealing resistance mutations that exist in the quasispecies below the Sanger detection threshold. However, the clinical significance of low-frequency minority variants detected by next-generation sequencing is not fully established: some studies find that pre-existing minority variants predict treatment failure, while others find they do not reliably affect outcomes. Next-generation sequencing remains a genotypic method that identifies mutations; phenotypic testing measures drug susceptibility directly in cell culture.

Correct Answer

A — M184V is a discrimination mutation that alters the reverse transcriptase active site to reduce incorporation of lamivudine and emtricitabine analogues relative to natural substrates; the same structural change impairs the excision activity that thymidine analogue mutations confer, reducing the reverse transcriptase's ability to remove incorporated zidovudine and tenofovir from the growing chain

Rationale

M184V belongs to the discrimination mutation category of nucleoside reverse transcriptase inhibitor resistance. Discrimination mutations alter the reverse transcriptase active site geometry to distinguish more effectively between the natural nucleotide substrate and the drug analogue, reducing the rate of drug incorporation relative to the natural substrate. For M184V, this discrimination is highly selective for lamivudine and emtricitabine, producing high-level resistance to these agents. The same structural change in the active site impairs the pyrophosphorolytic excision mechanism that thymidine analogue mutations exploit — mutations at the zidovudine and tenofovir binding region of the active site confer excision-type resistance, and M184V partially antagonizes this excision activity, resulting in increased susceptibility to zidovudine and tenofovir. This is the mechanistic basis for retaining lamivudine or emtricitabine in salvage regimens even after M184V is detected.

Correct Answer

C — Although resistant variants pre-exist for any single drug target, the probability that a single virion simultaneously carries independent resistance mutations against three mechanistically distinct targets is vanishingly small, making treatment failure through resistance selection improbable when viral replication is fully suppressed

Rationale

The quasispecies principle establishes that resistant variants pre-exist against any single drug target before treatment begins. The power of combination therapy is mathematical: while every possible single-point mutation exists in the pre-treatment quasispecies, the probability of any single viral genome simultaneously harboring independent resistance mutations against three mechanistically distinct drug targets — each mutation arising independently — is the product of three low probabilities, making such triple-resistant variants extraordinarily rare in the pre-treatment population. When three drugs suppress HIV replication simultaneously, the few triple-resistant variants that might exist have no replicative advantage and are maintained at frequencies too low to drive treatment failure. This principle — mechanistic diversity across targets multiplies the resistance barrier — applies directly to pandemic preparedness planning: stockpiling agents targeting multiple distinct viral steps provides the same combinatorial resistance protection for emerging pathogens that effective antiretroviral therapy provides for HIV.

Correct Answer

B — The low genetic resistance barrier of efavirenz means a single K103N mutation confers high-level resistance to efavirenz and nevirapine; doravirine has a distinct resistance mutation profile and may retain activity, but the regimen should be reassessed for full resistance testing before switching

Rationale

Efavirenz and nevirapine share a low genetic resistance barrier — a single K103N mutation in the reverse transcriptase gene confers high-level resistance to both agents by altering the hydrophobic non-nucleoside reverse transcriptase inhibitor binding pocket. K103N is not an excision or discrimination mutation; it is a binding site alteration that prevents drug docking in the allosteric pocket. Because K103N has low fitness cost, it persists in the quasispecies even after efavirenz is discontinued. Doravirine and rilpivirine have distinct resistance mutation profiles that differ from the K103N-dominated pathway, and either may retain activity against K103N-carrying virus; however, the full resistance testing result should guide regimen selection. Switching within the same class without resistance testing risks further resistance accumulation.

Correct Answer

D — Tenofovir disoproxil fumarate or tenofovir alafenamide, because M204V substantially reduces lamivudine and telbivudine susceptibility but has only modest effects on tenofovir susceptibility, and tenofovir has no confirmed resistance in treatment-naive patients

Rationale

M204V in the hepatitis B virus reverse transcriptase confers high-level resistance to lamivudine and telbivudine but has only modest effects on tenofovir susceptibility. Tenofovir disoproxil fumarate and tenofovir alafenamide are the preferred switch agents in this setting because of their distinct structural interaction with the reverse transcriptase active site and their exceptional resistance profile — no confirmed resistance mutations have emerged in treatment-naive patients through 8 or more years of phase 3 surveillance. Entecavir would be a problematic choice because pre-existing M204V substantially reduces the entecavir resistance barrier, and entecavir resistance emerges rapidly in lamivudine-experienced patients with M204V. Telbivudine carries the same cross-resistance pattern as lamivudine for M204V. Adefovir has higher resistance rates than tenofovir and is no longer a preferred agent.

Correct Answer

A — Baseline NS5A resistance-associated substitutions reduce the efficacy of first-generation NS5A inhibitor-containing regimens in genotype 1a-infected patients but do not meaningfully reduce sustained virologic response rates with second-generation pangenotypic regimens such as glecaprevir-pibrentasvir or sofosbuvir-velpatasvir

Rationale

NS5A resistance-associated substitutions pre-exist in approximately 10 to 15 percent of hepatitis C virus genotype 1a-infected patients and can reduce the activity of first-generation NS5A inhibitors such as ledipasvir and elbasvir. However, second-generation pangenotypic NS5A inhibitor-containing combinations — particularly glecaprevir-pibrentasvir and sofosbuvir-velpatasvir — have substantially higher resistance barriers and maintain high sustained virologic response rates at 12 weeks in patients with pre-existing NS5A resistance-associated substitutions. Pre-treatment resistance testing for NS5A substitutions is therefore relevant primarily when considering elbasvir-grazoprevir for genotype 1a-infected patients, but does not require avoidance of pangenotypic regimens that are the current standard of care. The finding in this patient does not preclude treatment with a modern combination.

Correct Answer

C — Resistance to any single mechanistic class is an inevitable consequence of quasispecies pre-existence and selection pressure during widespread use; stockpiling mechanistically non-overlapping agents ensures that a pathogen that develops resistance to one class faces a second agent with a distinct target, preventing complete therapeutic failure

Rationale

The quasispecies principle establishes that resistant variants pre-exist before drug exposure in any rapidly replicating ribonucleic acid virus population. Widespread use of a single mechanistic class during a pandemic would apply enormous selection pressure across a global viral population, amplifying pre-existing resistant variants and potentially driving resistance to clinical predominance — as occurred with adamantane resistance in influenza A. Maintaining stockpiles of mechanistically non-overlapping agents ensures that if resistance to one class emerges, agents targeting distinct viral steps remain effective. This is the same resistance principle that underlies combination antiretroviral therapy for HIV and combination direct-acting antiviral therapy for hepatitis C virus: no single mutation can simultaneously overcome two agents with mechanistically distinct and non-overlapping targets. The COVID-19 example — where sotrovimab lost activity against Omicron through spike epitope mutations while nirmatrelvir (targeting a conserved protease) retained activity — illustrates this principle in a real pandemic setting.